<DOC>
	<DOCNO>NCT01713608</DOCNO>
	<brief_summary>A randomised , placebo-controlled , dose-escalation study investigate safety toleration OZ439 OD 3 day healthy male female volunteer . The study aim : - To determine safety tolerability ascend dos OZ439 OD three day . - To assess pharmacokinetic parameter ascend dos OZ439 give OD . - To identify maximum tolerate dose OZ439 administer .</brief_summary>
	<brief_title>A Dose-escalation Study Investigate Safety Toleration OZ439</brief_title>
	<detailed_description>This study conduct randomise , placebo-controlled dose-escalation design OZ439 OD administer full fat milk three day healthy male female subject 18 55 year age , use feature adaptive study design . The study expect three cohort total 36 healthy male female subject . An additional two cohort may use require . The result study inform maximum tolerate exposure OZ439 follow OD dose three day subject fast .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<criteria>Inclusions : 1. healthy male female race age 18 55 year 2 . BMI 18 30 kg/m2 inclusive screen 3 . Agree use acceptable method contraception childbearing potential 4 . Capable understand comply requirement protocol must sign informed consent form 5 . Females either child bearing potential confirm postmenopausal . Postmenopausal define amenorrheic 12 month without alternative medical cause screen FSH level â‰¥ 25.8 IU/L Exclusions : 1 . Male subject female partner ( ) ( ) pregnant lactate time first administration study medication 2 . Clinically significant disease condition disease might affect drug absorption , distribution excretion 3 . History allergic reaction artemisininbased compound clinically relevant allergy drug food 4 . Clinically relevant history soya cow 's milk intolerance/allergy 5 . Clinically significant abnormal laboratory , vital sign safety finding determine medical history , physical examination evaluation conduct screen admission 6 . Electrocardiogram ( ECG ) abnormalities standard 12lead ECG ( screen ) and/or 24hour 5 lead Holter ECG ( screen ) 7 . Any abnormality rhythm , conduction morphology rest ECG may interfere interpretation QTc interval change 8 . Prolonged QTcF &gt; 450 m shorten QTcF &lt; 340 m , family history Long QT Syndrome 9 . History current evidence clinically relevant cardiovascular , pulmonary , hepatic , renal , gastrointestinal , haematological , endocrinological , metabolic , neurological , psychiatric , disease 10 . Positive result serology test Hepatitis B Surface Antigen ( HbsAg ) , anti Hepatitis core antibody ( anti HBc Ig G [ anti HBc IgM IgG positive ] , Hepatitis C antibody ( anti HCV ) , HIV 1 2 antibody ( anti HIV 1/2 ) 11 . Confirmed positive result urine drug screen ( amphetamine , benzodiazepine , cocaine , cannabinoids , opiate , barbiturate , methadone ) alcohol breath test screen admission 12 . History clinical evidence alcohol drug abuse . Alcohol abuse define regular weekly intake 21 unit male 14 unit female ; drug abuse define compulsive , repetitive and/or chronic use drug substance without problem relate use and/or stop reduction dose lead withdrawal symptoms 13 . Is pregnant lactating ( female subject childbearing potential must negative pregnancy test screen admission ) 14 . Mentally handicap 15 . Participation drug trial within 90 day prior first drug administration 16 . Use medication ( incl . overthecounter ( OTC ) medication ) within 2 week prior drug administration ( Day 1 ) within less 10 time elimination halflife respective drug , anticipate concomitant medication treatment period , ( whichever longer ) , include herbal , traditional alternative medication . Excluding oral contraceptive ( combination oestrogen/progesterone pills ) , injectable progesterone subdermal implant . Limited amount ( 4g/day 2 day ) paracetamol permit treatment AEs 17 . Treatment herbal supplement 7 day prior drug administration , use vitamins 48 hour prior drug administration 18 . Is permit use strong inhibitor and/or inducer CYP450 within 21 day prior plan first drug administration 19 . Subjects vein unsuitable intravenous puncture cannulation either arm ( e.g . vein difficult locate , access puncture vein tendency rupture puncture ) 20 . Blood ALT , AST bilirubin normal range screen admission 21 . Donation 500 mL blood within 90 day prior drug administration 22 . Subjects must nonsmoker least three month prior first drug administration 23 . Any circumstance condition , , opinion PI , may affect full participation trial compliance protocol 24 . Legal incapacity limit legal capacity screen 25 . Subjects vegetarian , vegan dietary restriction conflict study standardise menu</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>malaria</keyword>
	<keyword>dose escalation</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>maximum tolerate dose</keyword>
</DOC>